ITGB1 and neoplasm: OS2966, a neutralizing ITGB1 monoclonal antibody, attenuates aggressive tumor phenotypes in vitro and inhibits growth of antiangiogenic therapy-resistant tumor xenografts in vivo [167], constituting a potential therapeutic opportunity.